For More Details, Request for a Sample of this Research Report: br br The global paroxysmal nocturnal hemoglobinuria industry, valued at US$ 3.8 billion in 2023, is projected to grow at a CAGR of 10.8 from 2024 to 2034, reaching US$ 11.7 billion by 2034.br br Rise in geriatric population and influx of biologics are augmenting the paroxysmal nocturnal hemoglobinuria market demand. Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic disorder affecting nearly 20,000 people across the globe. It is characterized by three major manifestations, i.e. pancytopenia, persistent intravascular hemolysis, and thrombosis.